Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 217 people enrolled
- Started
- 18 Aug 2017
- Ended
- 16 May 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Diet
- Record updated
- 7 April 2025
- Why it stopped
- Interim analysis determined that study reached a safety stopping rule
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18 years or older
- Undergoing treatment for hematologic malignancies or HSCT as outlined below:
- Underlying diagnosis for non-HSCT patients:
- Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) receiving induction or reinduction chemotherapy; OR
- Acute lymphoblastic leukemia (ALL) receiving an intensive induction chemotherapy (e.g., HyperCVAD±R, CALGB9251, Larsons protocol) with an expected duration of neutropenia of ≥7 days; OR
- Allogeneic or autologous HSCT for any indication. For patients undergoing reduced intensity conditioning, only those regimens in which the expected neutropenia is ≥ 7 days are permitted and the patient must reside in the hospital
- Expected duration of neutropenia of ≥ 7 days
Who cannot take part
- Use of anti infectives for treatment of active systemic infections within 7 days prior to initiation of study diet
- Untreated major infection at presentation
- Patients with uncontrolled invasive fungal infection (defined as those who have not completed at least 6 weeks of treatment; or who are symptomatic with two CT scans, at least 1 week apart showing uncontrolled disease at the time of initiation of study diet)
- Uncontrolled HIV, Hepatitis B and C infection
- Receipt of nutrition via enteral tube or total parenteral nutrition at the time of enrollment
- Patients unwilling to eat fresh fruit and/or vegetables
- Planned management of neutropenia in the outpatient setting
Where in United States
- UF Health Cancer CenterGainesville, United States
About the trial
What the trial wants to find out
This is an open-label, two-arm, phase III non-inferiority trial to evaluate the safety of a liberalized hospital diet inclusive of fresh fruits and vegetables to a neutropenic diet in patients with prolonged neutropenia. Both cohorts and diets will adhere to the hygiene and common sense advice listed in the FDA-endorsed food safety guidelines.
The 2 groups in the trial
- Liberalized Hospital Diet (Diet A)Existing treatment, for comparison
Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.
Treatment: Diet
- Neutropenic Diet (Diet B)Existing treatment, for comparison
Diet B is the hospital neutropenic diet.
Treatment: Diet
Results explained
A paper that names this trial, explained in plain words.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Randomized, Clinical Trial Comparing Two Diets in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) or Remission Induction Chemotherapy for Acute Leukemia and Myelodysplastic Syndrome (UF-BMT-LDND-101)
- Publications
- Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026
- Record updated
- 7 April 2025